Snowden Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Snowden Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,047	Closed	-$580K	–	1221
2024 Q2	$580K	Sell	7,047 -279	-4%	-$23.2K	0.02%	679
2024 Q1	$640K	Sell	7,326 -80	-1%	-$7.16K	0.02%	653
2023 Q4	$714K	Buy	7,406 +1,766	+31%	+$156K	0.03%	540
2023 Q3	$499K	Sell	5,640 -11	-0.2%	-$979	0.02%	656
2023 Q2	$490K	Sell	5,651 -40	-0.7%	-$3.76K	0.02%	745
2023 Q1	$553K	Buy	5,691 +245	+4%	+$25.4K	0.02%	689
2022 Q4	$564K	Buy	5,446 +587	+12%	+$55.1K	0.02%	657
2022 Q3	$411K	Buy	4,859 +1,782	+58%	+$159K	0.02%	730
2022 Q2	$254K	Buy	+3,077	New	+$245K	0.01%	938
2022 Q1	–	Sell	-217	Closed	-$19K	–	1169
2021 Q4	$19K	Buy	+217	New	+$17.9K	﹤0.01%	1341

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Snowden Capital Advisors's BMRN Position: Q3 2024 in Review

Snowden Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 7,047 shares — an estimated $580K sold.

Snowden Capital Advisors first reported a position in BMRN in Q4 2021 and held it in 10 quarters. The position peaked at $714K in Q4 2023. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Snowden Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Snowden Capital Advisors sold 7,047 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $580K.
Snowden Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Snowden Capital Advisors's BioMarin Pharmaceuticals position peaked at $714K in Q4 2023.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Snowden Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.